5 Stocks Pushing The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 161 points (1.0%) at 15,537 as of Monday, Sept. 16, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 2,425 issues advancing vs. 535 declining with 80 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.9%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 1.9%, Valeant Pharmaceuticals International ( VRX), up 1.8%, Novo Nordisk A/S ( NVO), up 1.6%, AstraZeneca ( AZN), up 1.6% and Eli Lilly and Company ( LLY), up 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Novartis ( NVS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novartis is down $0.70 (-0.9%) to $75.50 on heavy volume. Thus far, 1.4 million shares of Novartis exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $75.28-$76.01 after having opened the day at $76.00 as compared to the previous trading day's close of $76.20.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $186.4 billion and is part of the health care sector. Shares are up 20.3% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $1.25 (-1.6%) to $77.00 on average volume. Thus far, 736,112 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $76.92-$79.49 after having opened the day at $79.06 as compared to the previous trading day's close of $78.25.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $19.0 billion and is part of the health care sector. Shares are up 94.3% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is down $0.36 (-0.9%) to $37.98 on average volume. Thus far, 2.0 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $37.97-$38.34 after having opened the day at $38.27 as compared to the previous trading day's close of $38.34.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $32.9 billion and is part of the health care sector. Shares are up 4.1% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Celgene Corporation ( CELG) is down $0.93 (-0.6%) to $148.55 on average volume. Thus far, 1.4 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $147.95-$151.20 after having opened the day at $150.80 as compared to the previous trading day's close of $149.48.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $61.5 billion and is part of the health care sector. Shares are up 90.7% year to date as of the close of trading on Friday. Currently there are 20 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Celgene Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $0.38 (-0.6%) to $63.15 on average volume. Thus far, 3.7 million shares of Gilead exchanged hands as compared to its average daily volume of 8.4 million shares. The stock has ranged in price between $62.73-$64.21 after having opened the day at $64.08 as compared to the previous trading day's close of $63.53.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $96.7 billion and is part of the health care sector. Shares are up 72.0% year to date as of the close of trading on Friday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Jim Cramer: Intuit Had a Fantastic Quarter

Jim Cramer: Intuit Had a Fantastic Quarter

Jim Cramer on Foot Locker's Earnings: Nike Is a Buy

Jim Cramer on Foot Locker's Earnings: Nike Is a Buy

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%